Engimmune Therapeutics
Engimmune Therapeutics is a platform engineering next-generation T cell receptor therapies founded in 2021 by Søren Mouritsen.
2
Funding Rounds
$31.8m
Money raised
Overview
Engimmune Therapeutics is a platform engineering next-generation T cell receptor therapies founded in 2021 by Søren Mouritsen.
- Website:
- Business model: B2B
- Headquarters: Basel
- Social accounts: linkedin
| Name | Phone | Social networks | |
|---|---|---|---|
| Ro***** Va************** | - | - | - |
| S�**** Mo******* | - | - |
Funding series
Funding Series Analysis
The company Engimmune Therapeutics has raised a total of $15.8m in funding over 2 rounds.
Key Insights:
- Engimmune Therapeutics Seed round, May 2022: $15.8m
- Engimmune Therapeutics 2022 Seed Funding Round: $16m
Engimmune Therapeutics Seed round, May 2022
$15.8m
Engimmune Therapeutics 2022 Seed Funding Round
$16m
Industries
Engimmune Therapeutics is active in the following industries: